This study will examine the effect of a single high dose of psilocybin therapy (30 mg) versus a very low dose (1 mg) as an adjunctive therapy to individuals undergoing standard-of-care buprenorphine treatment for Opioid use disorder (OUD). Effects of adjunctive psilocybin will be determined for longitudinal outcomes of opioid abstinence, compliance with buprenorphine maintenance, quality of life, and mood.

开始日期2027-04-01

申办/合作机构

The Johns Hopkins University

NCT07226232

/ Not yet recruiting临床3期IIT

A Multi-site Randomized Controlled Trial of Psilocybin for Treatment-Resistant Depression (TRD) in Veterans

The purpose of this multi-site randomized controlled trial is to evaluate the efficacy and risks of psilocybin for the treatment of depression in U.S. military Veterans with and without (±) concurrent posttraumatic stress disorder.

开始日期2026-06-01

申办/合作机构

VA Office of Research and Development

NCT07306364

/ Not yet recruiting临床2期IIT

Psilocybin in Chronic Low Back Pain: An Integrative Study of Lab-Based Mechanisms and Real-World Physical Therapy Outcomes

The purpose of this research study is to investigate whether a single administration of psilocybin can improve interoceptive awareness (awareness of bodily sensations) in individuals with chronic low back pain undergoing physical therapy, and whether these improvements are linked to pain relief and better physical therapy outcomes.

开始日期2026-06-01

申办/合作机构

Yale University

[+1]

100 项与裸盖菇素相关的临床结果

登录后查看更多信息

100 项与裸盖菇素相关的转化医学

登录后查看更多信息

100 项与裸盖菇素相关的专利（医药）

登录后查看更多信息

2,343

项与裸盖菇素相关的文献（医药）

2026-04-01·JOURNAL OF AFFECTIVE DISORDERS

The effect of dextromethorphan on reward-related behaviors: A systematic review of preclinical and clinical evidence

Review

作者: Le, Gia Han ; Wong, Sabrina ; Teopiz, Kayla M ; McIntyre, Roger S

INTRODUCTION:

Extant literature suggests that anhedonia, defined as a loss of the ability to feel pleasure or interest, is subserved by dysregulation of reward processing in the central nervous system. Dextromethorphan (DXM), an uncompetitive N-Methyl-d-Aspartate (NMDA) receptor antagonist and sigma-1 (σ1) receptor agonist, is a glutamatergic modulator with antidepressant properties. The effect of DXM on reward-related outcomes remains inadequately characterized. Herein, we conducted a systematic review of extant literature reporting on the effects of DXM on reward-related behaviors in both preclinical and clinical studies.

METHODS:

A systematic search of the literature was conducted on online databases (PubMed, OVID, Scopus, Web of Science) of published articles from inception to January 2025. Preclinical and clinical studies that reported on the effect of DXM on reward outcomes were assessed.

RESULTS:

Preclinical studies (n = 13) indicate that administration of DXM attenuates reward-seeking behavior in rats as measured primarily by performance in the conditioned place preference test and behavioral sensitization. In a single human study (n = 1) evaluating DXM in healthy participants (n = 20), self-reported drug-liking for DXM (400 mg/70 kg) was significantly lower in comparison to psilocybin (20 mg and 30 mg) at 7 h after the dosing session.

DISCUSSION:

Extant literature suggests that DXM administration attenuates reward-related behaviors in rats. There is a paucity of human studies investigating the effect of DXM on reward outcomes. Future research should prioritize the investigation of the effect of DXM on reward function using validated reward paradigms in persons with anhedonia.

2026-04-01·EUROPEAN NEUROPSYCHOPHARMACOLOGY

Bridging the reporting gap: Application of the ReSPCT guidelines in psilocybin clinical trial protocols

Article

作者: Kwaśny, Aleksander ; Swieczkowski, Damian ; Cubała, Wiesław Jerzy ; Sadko, Krzysztof

Psilocybin-assisted therapies are increasingly studied for Major Depressive Disorder (MDD) and Treatment-Resistant Depression (TRD), and methodological rigor requires both pharmacological evaluation and consistent reporting of non-pharmacological variables that influence therapeutic outcomes. To address this need, the ReSPCT (Reporting of Setting in Psychedelic Clinical Trials) guidelines were recently introduced, providing a 30-item framework for standardized reporting of set and setting. This study aimed to evaluate how current psilocybin clinical trial protocols incorporate these elements and to identify domains requiring improvement. We systematically searched ClinicalTrials.gov and the EU Clinical Trials Information System (CTIS) for interventional psilocybin studies targeting MDD or TRD, including protocols listing depression as a primary condition. By June 21, 2025, 13 protocols (11 Phase II and 2 Phase III) met the inclusion criteria. Each protocol was assessed using the ReSPCT checklist, yielding a total of 390 item-level assessments rated on a four-point scale. Overall, 61 of 390 entries (15.6%) demonstrated full compliance, 252 (64.6%) partial compliance, and 77 (19.7%) provided no relevant information. Procedural elements, such as medical and experimental procedures (100% compliance), focus and main activities (92.3%), number of sessions (69.2%), and dosing regimens (53.8%), were consistently reported. In contrast, contextual and equity-related domains were markedly underreported: 84.6% of protocols lacked information on cultural competence and safety, 92.3% did not describe objects or decorations, and 84.6% failed to report access to nature. These findings indicate that while procedural safeguards are well documented, critical contextual and equity-relevant aspects remain insufficiently reported. Adopting ReSPCT guidelines may improve transparency and reproducibility.

2026-03-01·PSYCHIATRY RESEARCH

Adverse events associated with classic psychedelics and MDMA: a real-world population-based study using the WHO pharmacovigilance database (VigiBase)

Article

作者: Sinyor, Mark ; Nestor, Sean M ; Alam, Fahad ; Giacobbe, Peter ; Syed, Omer A ; Husain, Muhammad Ishrat

Psychedelic use has greatly increased within clinical and recreational settings over recent years. While demonstrating a favorable safety profile within certain clinical populations, little empirical research has explored safety of psychedelic use within real-world samples. Using the World Health Organization (WHO) VigiBase, a comprehensive global pharmacovigilance database with voluntary spontaneous reporting of adverse events (AEs) from real-world clinical and recreational populations, we examined reports for classic psychedelics and MDMA. Most reports were made for MDMA (n = 1573) and LSD (n = 394), while psilocybin (n = 56), DMT (n = 18), and mescaline (n = 15) had fewer reports. The most common AEs for all substances were psychiatric in nature, specifically surrounding substance or drug abuse and dependence. Reports of overdose constituted 1.1 to 1.7 % of total AEs. Pregnancy-related and congenital disorders were rare. Compared to the acetaminophen control, LSD and MDMA were associated with significantly greater odds for the reported AEs of alcohol abuse (LSD: ROR=45.7, 95 % CI: 27.2 - 76.9; MDMA: ROR=19.2, 95 % CI: 12.2 - 30.4), substance use disorder (LSD: ROR=71.1, 95 % CI: 36.3 - 139.2; MDMA: ROR=129.9, 95 % CI: 78.4 - 215.5) and substance dependence (LSD: ROR=215.1, 95 % CI: 69.0 - 670.3; MDMA: ROR=76.8, 95 % CI: 25.5 - 231.8). These reports were also greater than those associated with the external positive control, oxycodone. Taken together, this exploratory study provides the first analysis of AEs associated with psychedelics reported to a global pharmacovigilance database and can inform their real-world safety. Findings should be considered in light of limitations surrounding co-use of other substances and potential deterrence towards reporting use of illicit substances.

1,194

项与裸盖菇素相关的新闻（医药）

2026-01-26

·BioSpace

Optimi Health Completes First 2026 Production of MDMA and Psilocybin Capsules

Australia’s Department of Health has issued import permits for Optimi’s MDMA and psilocybin capsules for use under the Authorised Prescriber Scheme Vancouver, British Columbia--(News - January 26, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of pharmaceutical psychedelic drug products, today reported that it has completed a production cycle for its MDMA and psilocybin capsules intended for supply into Australia under the Authorised Prescriber Scheme. The completed batch consists of 1,000 MDMA capsules in a 60 mg dosage form and 1,000 naturally derived psilocybin capsules in a 5 mg dosage form. Final packaging, labelling, and batch release were completed in accordance with Optimi's Drug Establishment Licence issued by Health Canada. The capsules are GMP-compliant and supported by Certificates of Analysis confirming conformance with applicable quality specifications, following receipt of the required Australian import permits. To view an enhanced version of this graphic, please visit: "This production run has been released and approved for import, allowing Optimi to continue supplying MDMA and psilocybin into Australia's regulated healthcare system," said Dane Stevens, Chief Executive Officer of Optimi Health. "Completing this first production cycle of 2026 positions us to expand access across the country for patients suffering from PTSD and TRD." Post-Traumatic Stress Disorder (PTSD) and Treatment-Resistant Depression (TRD) represent significant unmet medical needs in Australia. National data published by the Australian Bureau of Statistics indicate that approximately 5-6% of Australians experience PTSD in a given year, representing roughly 1.3 to 1.5 million people. According to the Australian Institute of Health and Welfare, more than 1.3 million Australians are affected by depressive disorders, and clinical research suggests that around one-third of individuals with major depressive disorder do not respond adequately to standard treatments. Australian clinics, hospital networks, and programs operating under the Authorised Prescriber Scheme may seek information regarding access through Mind Medicine Australia at info@mindmedicineaustralia.org . For global inquiries outside of Australia, please contact the Company at sales@optimihealth.ca . For more information, please contact: Dane Stevens, CEO Optimi Health Corp. Telephone: (778) 761-4551 investors@optimihealth.ca Investor Relations Contact Lucas A. Zimmerman Managing Director MZ Group - MZ North America (262) 357-2918 OPTHF@mzgroup.us About Optimi Health Corp. Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) is a leading producer of prescribed psychedelic treatments for mental health therapies. As a Health Canada-licensed, GMP compliant pharmaceutical manufacturer producing validated MDMA and botanical psilocybin products from two 10,000-square-foot facilities in British Columbia, Optimi supplies active pharmaceutical ingredients and finished dosage forms to regulated channels, with products currently in market for prescription use in Australia via the Authorized Prescriber Scheme and accessible in Canada through the Special Access Program. For more information, please visit . Forward-Looking Statements This news release contains forward-looking statements and forward-looking information within the meaning of Canadian securities legislation (collectively, " forward-looking statements "), including with respect to the role of psychedelic medicines in insured mental health care. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive uncertainties, and contingencies, certain of which are unknown. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions, or future events or performance (often, but not always, through the use of words or phrases such as "will likely result," "are expected to," "expects," "will continue," "is anticipated," "anticipates," "believes," "estimated," "intends," "plans," "forecast," "projection," "strategy," "objective," and "outlook") are not historical facts and may be forward-looking statements. These statements may involve estimates, assumptions, and uncertainties that could cause actual results or outcomes to differ materially from those expressed in such forward-looking statements. No assurance can be given that these expectations will prove to be correct, and such forward-looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release. Forward-looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond the Company's control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. Such risk factors include but are not limited to those factors which are discussed in the Company's continuous disclosure filings available under its SEDAR+ pro . Except as expressly required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for the Company to predict all of them or assess the impact of each factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement. Neither the Canadian Securities Exchange nor the Canadian Investment Regulatory Organization accepts responsibility for the adequacy or accuracy of this release. To view the source version of this press release, please visit

2026-01-26

·drugs

Millions Of Americans Are Microdosing Psychedelics, Survey Finds

MONDAY, Jan. 26, 2026 — Psychedelics are catching on in the United States, but not always to find one’s third eye or reach another plane of reality, a new study says. An estimated 10 million U.S. adults microdosed psilocybin, LSD or MDMA in 2025, according to research published by the think-tank RAND. Researchers found that microdosing — taking a very small dose without the intention of reaching an altered state of consciousness — is common among people who use psychedelics. “There is an emerging discussion about the effects of microdosing on creativity, well-being and mental health, but until now little was known about how common it is,” lead investigator Michelle Priest , a RAND research project specialist, said in a news release. “Our findings suggest that for those who use psychedelics, taking small doses is a big deal,” Priest said. People who microdose do so for many reasons, including managing symptoms of anxiety and depression or improving mood and creativity, researchers said in background notes. Overall, psychedelics are being examined for a wide array of potential mental health benefits, including as a promising treatment for mood disorders, PTSD, and substance use disorders, according to the American Psychological Association . The drugs remain prohibited at the federal level, but some states and cities have passed laws allowing their use for medicinal purposes, researchers said. To estimate how widespread psychedelic use is in the U.S., RAND conducted a survey in September of 10,122 American adults. The survey asked about their use of 11 psychedelic substances, as well as whether they took microdoses or full doses of the drugs. Results revealed surprisingly widespread interest in microdosing, showing that many users are taking psychedelics not to get high but to gain other benefits from the drugs. Regardless of dosing, the five most commonly used psychedelics were psilocybin (11 million adults); MDMA (4.7 million); Amanita muscaria mushrooms (3.5 million); ketamine (3.3 million); and LSD (3 million). “I was not surprised to see psilocybin mushrooms at the top of the list,” researcher Beau Kilmer , co-director of the RAND Drug Policy Research Center, said in a news release. “But I was a bit surprised to see another mushroom, Amanita muscaria, so high on the list.” Also known as fly agaric mushrooms, Amanita muscaria mushrooms can produce euphoria and altered perceptions, researchers said. But they’re also toxic, according to the American College of Emergency Physicians . These shrooms can cause nausea, vomiting, loss of muscle control and seizures. The new study is titled U.S. Psychedelic Use and Microdosing in 2025 . Sources RAND, news release, Jan. 21, 2026

临床结果

2026-01-23

·药明康德

2026年上半年值得关注的10项临床试验

近日，行业媒体BioPharma Dive发布专题报道，从众多在研项目中选出10项有望在2026年上半年公布结果的重要临床试验。这些试验聚焦肥胖症、传染病、罕见病等多个治疗领域。本文将结合该文章及公开资料，与读者分享这些值得关注的临床试验。若您想阅读完整报告，可点击文末“阅读原文/Read More”。药物名称：Retatrutide 公司：礼来（Eli Lilly and Company）临床试验：TRIUMPH-1、TRIUMPH-2、TRIUMPH-3 Retatrutide是一款潜在“first-in-class”葡萄糖依赖性促胰岛素多肽（GIP）、胰高血糖素样肽-1（GLP-1）和胰高血糖素（glucagon）受体靶向三重激动剂。2025年12月公布的3期临床试验TRIUMPH-4的结果显示，在无糖尿病、但患有肥胖或超重并合并膝骨关节炎的成年患者中，retatrutide可平均降低体重最多达28.7%。在2026年中，名为TRIUMPH-1、TRIUMPH-2和TRIUMPH-3的3项关键性临床试验将获得结果。第一项针对肥胖人群，第二项针对肥胖合并糖尿病患者，第三项则针对肥胖且已确诊心血管疾病的人群。这三项试验合计入组超过5000名受试者。这些试验结果将进一步确认retatrutide治疗肥胖和心血管代谢疾病方面的潜力。药物名称：CD388 公司：默沙东（MSD）、Cidara Therapeutics 临床试验：ANCHOR 最初由Cidara Therapeutics开发的CD388由小分子神经氨酸酶抑制剂与专有的人源抗体Fc片段稳定偶联而成，旨在预防甲型和乙型流感。在2b期临床试验中，CD388在最高剂量下表现出76%的流感预防效力，而传统流感疫苗的平均预防效力通常为40%左右。去年11月，默沙东收购了Cidara公司，获得这款长效预防性疗法。CD388目前正在后期临床试验ANCHOR中接受评估，计划入组约6000名受试者。Cidara表示试验已达到入组目标，并计划在2026年第一季度开展期中分析。药物名称：RGX-202 公司：REGENXBIO 临床试验：AFFINITY DUCHENNE RGX-202是一种表达微抗肌萎缩蛋白（microdystrophin）的基因疗法，旨在改善杜氏肌营养不良症患者的肌肉功能和预后。RGX-202的独特之处在于编码的微抗肌萎缩蛋白中包含了关键的C末端（CT）结构域，在临床前研究中，CT结构域已被证明可保护肌肉免受收缩引起的压力并改善其自我修复能力。去年5月公布的1/2期临床试验数据显示，接受剂量水平2的RGX-202治疗的患者在治疗后第9个月与第12个月均展现出持续的功能改善，表现优于外部自然病程对照组。该公司预计在今年年初公布临床试验3期部分的结果。药物名称：Pelacarsen 公司：诺华（Novartis）、Ionis Pharmaceuticals 临床试验：Lp（a）HORIZON 反义寡核苷酸疗法pelacarsen靶向脂蛋白（a）——Lp（a），它是影响全球多达20%人群的心血管疾病的独立遗传风险因素。Lp（a）水平是由基因所决定，不受生活方式改变影响，因此患者无法通过改善饮食或增加体力活动来充分控制其Lp（a）水平。在此前的临床试验中，pelacarsen已被证明能将Lp（a）水平降低约80%。 Lp（a）HORIZON试验是一项大规模的全球性3期临床试验，用于评估pelacarsen降低重大心血管事件风险的效果。这项试验于2019年末启动，已入组超过8000名受试者，将在很大程度上回答降低Lp（a）是否能够减少心肌梗死和卒中等重大心血管事件。这项研究采用事件驱动设计，这意味着必须积累到一定数量的心血管事件后，研究人员才能评估pelacarsen是否具有心血管获益。药物名称：Lonvoguran ziclumeran（Lonvo-z）公司：Intellia Therapeutics 临床试验：HAELO Lonvo-z是一种体内CRISPR基因编辑候选疗法，通过脂质纳米颗粒（LNP）以mRNA形式递送CRISPR-Cas9基因编辑系统，靶向血浆前激肽释放酶（KLKB1）基因，使该基因失活以永久性降低血浆中激肽释放酶活性，从而防止遗传性血管性水肿（HAE）的发作。此前发布的2期临床试验数据显示，单次输注lonvo-z可使患者平均每月HAE发作率与安慰剂相比减少达81%。 Intellia公司预计将在2026年的年中公布全球关键性3期临床试验HAELO的顶线结果，如果结果积极，计划在2026年下半年递交lonvo-z的生物制品许可申请（BLA）。药物名称：Povetacicept 公司：Vertex Pharmaceuticals 临床试验：RAINIER Povetacicept是一种高效B细胞激活因子（BAFF）和增殖诱导配体（APRIL）的双重拮抗剂。BAFF与APRIL细胞因子因其在B细胞（特别是抗体分泌细胞）、T细胞和先天免疫细胞的激活、分化和/或生存中所扮演的角色，在多种自身免疫性疾病的发病机制中发挥关键作用。 2025年11月公布的试验结果显示，povetacicept在治疗肾病的早期临床研究中表现亮眼。48周数据显示，IgA肾病（IgAN）患者蛋白尿较基线下降64%，原发性膜性肾病（pMN）患者蛋白尿较基线下降82%，且两种疾病的估算肾小球滤过率（eGFR）均保持稳定。今年年初，使用povetacicept治疗IgAN患者的3期临床试验RAINIER将进行一次期中分析，如果结果积极，可能支持Vertex公司通过加速批准通道递交povetacicept的上市申请。药物名称：SRP-1001，SRP-1003 公司：Sarepta Therapeutics、Arrowhead Pharmaceuticals 临床试验：NCT06131983、NCT06138743 Sarepta Therapeutics公司在2024年与Arrowhead Pharmaceuticals达成研发合作，获得一系列siRNA疗法的研发权益，这些疗法针对肌肉、中枢神经系统和肺部疾病，其中4款已进入临床开发阶段。其中，SRP-1001用于治疗面肩肱型肌营养不良症（facioscapulohumeral muscular dystrophy）。另一款在研疗法SRP-1003则用于治疗一种肌强直性营养不良症（myotonic dystrophy）。Sarepta与Arrowhead预计将在今年年初公布两项临床试验的初步结果，展示药物的安全性以及其按预期发挥作用的潜力。 SRP-1001旨在降低骨骼肌中异常蛋白DUX4的产生。而SRP-1003的目标则是沉默来源于突变DMPK基因的有毒mRNA。药物名称：COMP360 公司：Compass Pathways 临床试验：COMP005、COMP006 COMP360是Compass Pathways公司开发的一种基于裸盖菇素（psilocybin）的专有制剂。去年6月，该公司表示，COMP360已在一项名为COMP005的后期临床研究中达到主要终点。与安慰剂相比，单次给药可在试验进行6周时显著降低难治性抑郁症患者的症状。该公司预计，在2026年头几个月内，Compass Pathways不仅将获得COMP005的26周随访数据，还将公布第二项3期试验的初步结果。该试验入组速度快于预期，名为COMP006，共招募了585名治疗抵抗性抑郁症（treatment-resistant depression）患者。药物名称：Myqorzo（aficamten）公司：Cytokinetics 临床试验：ACACIA-HCM Myqorzo是一种选择性小分子心肌肌球蛋白抑制剂。它通过直接抑制产力横桥的形成，减轻心肌过度收缩。在临床前模型中，Myqorzo通过结合心肌肌球蛋白上一个独特的选择性变构位点来降低心肌收缩力。它在2025年获得FDA批准，用于治疗有症状的梗阻性肥厚型心肌病（oHCM）成人患者。今年第二季度，Cytokinetics预计公布ACACIA-HCM的临床试验结果。该试验正在约500名非梗阻型HCM患者中评估Myqorzo的疗效，重点考察其在72周后是否能够显著改善峰值摄氧量（peak oxygen consumption），以及提升心脏健康评估量表的评分。如果试验结果积极，有望扩展Myqorzo用于治疗的患者群体。参考资料： [1] 10 clinical trials to watch in the first half of 2026. Retrieved January 23, 2026, from https://www.biopharmadive.com/news/biotech-pharma-clinical-trials-watch-2026/808255/ 免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

临床3期并购寡核苷酸临床2期疫苗

100 项与裸盖菇素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	裸盖菇素	-	DB11664

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
重度抑郁症	临床3期	美国	Usona Institute	2024-03-13
难治性抑郁症	临床3期	美国	Compass Pathways Plc	2023-01-19
腰痛	临床2期	美国	Yale University	2026-06-01
周围神经系统疾病	临床2期	美国	The University of Texas MD Anderson Cancer Center	2026-05-04
口吃	临床2期	美国	NYU Langone Health	2026-01-15
乳腺癌	临床2期	澳大利亚	Psyence Australia Pty Ltd.	2025-09-15
子宫内膜癌	临床2期	澳大利亚	Psyence Australia Pty Ltd.	2025-09-15
肾肿瘤	临床2期	澳大利亚	Psyence Australia Pty Ltd.	2025-09-15
皮肤黑色素瘤	临床2期	澳大利亚	Psyence Australia Pty Ltd.	2025-09-15
情绪障碍	临床2期	澳大利亚	Psyence Australia Pty Ltd.	2025-09-15

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04950608 (PATH, CTgov)	临床2期	疾病进展 \| 晚期癌症	15	Psilocybin	鏇淵廠網鑰憲糧構廠憲 = 糧簾窪鬱繭糧糧鬱繭壓鹽糧淵範鏇選願築構鹽 (鬱鹹觸衊齋淵網齋築繭, 網憲壓蓋鑰憲糧廠鹹構 ~ 憲範網顧簾繭齋選憲齋) 更多	-	2025-09-02
NCT04424225 (CTgov)	临床1期	致幻 \| 知觉障碍 \| 视觉抑制	10	Psilocybin (Psilocybin)	獵憲願簾製艱網鬱鏇選(壓淵蓋選夢顧衊築憲願) = 簾夢壓餘顧鬱齋簾壓範範範鹽觸廠獵餘願顧蓋 (積遞遞觸壓選鹹網遞獵, .11731) 更多	-	2025-06-27
NCT04424225 (CTgov)	临床1期	致幻 \| 知觉障碍 \| 视觉抑制	10	Niacin (Niacin)	獵憲願簾製艱網鬱鏇選(壓淵蓋選夢顧衊築憲願) = 製範鬱願顧鑰顧構網壓範範鹽觸廠獵餘願顧蓋 (積遞遞觸壓選鹹網遞獵, .04398) 更多	-	2025-06-27
NCT05312151 (CTgov)	临床2期	创伤后应激障碍	22	Psilocybin	窪淵鬱膚積淵壓構製鹹 = 憲顧繭製獵鬱觸選糧窪憲鹽膚獵襯鑰衊獵襯壓 (膚鹽夢願製鑰憲構衊廠, 築窪餘淵憲艱網獵糧窪 ~ 觸蓋淵簾獵簾壓衊淵醖) 更多	-	2025-06-13
NCT05847686 (CTgov)	临床1/2期	转移性肿瘤 \| 转移性实体瘤 \| 血液肿瘤 ... 更多	55	Counseling+Psilocybin	鏇觸淵窪壓網壓壓構艱 = 壓廠遞網膚憲艱壓積窪網鏇顧觸鹹醖築網遞齋 (積蓋遞鹽蓋廠壓醖繭顧, 醖範餘築鏇窪糧鬱夢鏇 ~ 構衊範夢衊網鹹構廠廠) 更多	-	2025-04-30
NCT05128162 (CTgov)	临床2期	纤维肌痛	17	Psilocybin	鏇積壓膚襯獵構鹹廠壓(憲繭醖選願網積顧糧網) = 獵廠壓壓廠範獵鏇選觸遞積醖餘鏇選願鬱製糧 (壓壓鏇繭淵顧淵築築遞, 憲壓糧築夢廠糧膚願築 ~ 鏇醖餘簾襯齋蓋鹽憲壓) 更多	-	2025-04-16
NCT04141501 (Pubmed \| EClinicalMedicine)	临床2期	酒精使用障碍	37	Psilocybin (25 mg)	憲鬱鬱製壓淵襯膚願積(鹽鹹鑰簾糧襯艱襯範鏇) = 齋製齋遞製願構觸醖鹽構糧鹽壓願廠膚餘鹽廠 (淵網憲糧積醖淵膚餘壓, 14.31 ~ 19.29) 更多	不佳	2025-04-01
NCT04141501 (Pubmed \| EClinicalMedicine)	临床2期	酒精使用障碍	37	Placebo (mannitol)	憲鬱鬱製壓淵襯膚願積(鹽鹹鑰簾糧襯艱襯範鏇) = 窪製餘觸襯襯顧選襯糧構糧鹽壓願廠膚餘鹽廠 (淵網憲糧積醖淵膚餘壓, 10.97 ~ 16.63) 更多	不佳	2025-04-01
NCT05163496 (CTgov)	临床3期	新冠肺炎后遗症 \| 职业倦怠 \| 创伤后应激障碍	30	Psilocybin (Psilocybin Arm)	顧淵餘遞憲簾憲簾製鏇(製鹹選積鏇網餘簾廠壓) = 糧窪鹹觸醖餘積遞鏇衊遞夢廠齋積繭鬱糧廠鏇 (選憲蓋遞築衊淵醖鑰積, 7.84) 更多	-	2025-03-18
NCT05163496 (CTgov)	临床3期	新冠肺炎后遗症 \| 职业倦怠 \| 创伤后应激障碍	30	Active placebo (Placebo)	顧淵餘遞憲簾憲簾製鏇(製鹹選積鏇網餘簾廠壓) = 鏇膚壓蓋糧遞築夢鏇壓遞夢廠齋積繭鬱糧廠鏇 (選憲蓋遞築衊淵醖鑰積, 7.32) 更多	-	2025-03-18
NCT04718792 (Company_Website \| Pubmed) 人工标引	临床2期	酒精使用障碍	10	PEX010	願簾觸糧鏇鬱窪鏇製選(窪廠遞觸獵醖襯觸艱築) = 醖衊襯襯觸鏇簾築築衊齋鹹鬱網獵憲壓願範膚 (糧廠齋顧糧構獵繭願鹽, −61.1 ~ −13.9) 更多	积极	2025-03-17
NCT04433858 (Pubmed \| J Affect Disord)	临床2期	难治性抑郁症	15	Psilocybin 25 mg	觸膚夢獵遞夢糧簾夢憲(餘製壓餘願餘糧構鏇餘) = 壓願壓壓壓廠製醖廠獵襯憲顧遞艱齋構簾積獵 (艱觸鑰簾網鑰獵選壓遞 ) 更多	积极	2025-01-01
NCT03429075 (Psilodep-RCT \| COMP360, CTgov)	临床2期	重度抑郁症	59	Psilocybin + Placebo (Psilocybin)	鹽積蓋遞淵構範醖範積(顧範構齋膚鹹製簾鏇繭) = 範憲糧顧齋構襯願願淵衊鏇願憲蓋鑰蓋網壓齋 (顧積簾構鹹艱繭遞遞齋, 0.45) 更多	-	2024-10-24
NCT03429075 (Psilodep-RCT \| COMP360, CTgov)	临床2期	重度抑郁症	59	Escitalopram+Psilocybin (Escitalopram)	鹽積蓋遞淵構範醖範積(顧範構齋膚鹹製簾鏇繭) = 簾餘鬱廠簾範艱淵築鬱衊鏇願憲蓋鑰蓋網壓齋 (顧積簾構鹹艱繭遞遞齋, 0.62) 更多	-	2024-10-24